Quest Diagnostics Stock Lags S&P 500 by 14 Percentage Points
3h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
quest-diagnosticsdgh
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Quest Diagnostics stock has underperformed the S&P 500 index over the past year, delivering a negative return while the broader market gained. Data published on 19 June 2026 shows the medical laboratory operator's share price posted a negative return of 8.7% over the prior 12-month period. Over the same timeframe, the S&P 500 index generated a positive total return of 5.9%. This performance gap of 14.6 percentage points signals investor concern over specific headwinds facing the clinical diagnostics sector.
Historical data shows Quest Diagnostics has typically exhibited low volatility and defensive characteristics relative to the broader market. During the market correction in 2022, for instance, the S&P 500 declined approximately 19% while Quest Diagnostics shares fell only around 12%. The current underperformance during a period of market gains is therefore a notable departure from its historical pattern.
The current macro backdrop includes a Federal Reserve policy rate holding at a 5.25%-5.50% range, placing pressure on healthcare utilization as consumers manage higher costs. The 10-year Treasury yield is at 4.31%, which increases the discount rate on future earnings for growth-sensitive sectors. These conditions have led investors to rotate capital away from slower-growth segments.
The immediate catalyst for the performance review is the conclusion of the 2026 first quarter earnings season. Major laboratory companies reported results that highlighted a persistent decline in revenue per requisition, a key profitability metric. This trend, coupled with moderating test volumes following the pandemic surge, has shifted investor focus to sustained organic growth challenges beyond COVID-19 testing.
Concrete financial metrics detail the scale of the underperformance. Quest Diagnostics stock price closed at $126.75 on 18 June 2026. The company's market capitalization stands at approximately $14.2 billion. Over the one-year period ending on that date, the stock's total return was -8.7%, while the S&P 500 Health Care Sector index returned -2.1%.
A direct comparison of key periods illustrates the widening gap. In the last six months, DGH returned -10.4% versus the S&P 500's +4.1%. The performance divergence accelerated following the company's first-quarter earnings report on 25 April 2026, which disclosed a 3.7% year-over-year drop in revenue. Peer LabCorp reported a similar revenue decline of 4.2% for the same quarter, indicating a sector-wide trend.
| Metric | Quest Diagnostics (DGH) | S&P 500 Index | Point Difference |
|---|---|---|---|
| 1-Year Total Return | -8.7% | +5.9% | -14.6 pts |
| YTD Return (as of 18 Jun) | -12.1% | +8.3% | -20.4 pts |
| Forward P/E Ratio | 13.2x | 20.5x | -7.3 pts |
This valuation discount reflects lower growth expectations embedded in the stock price.
The underperformance has direct second-order effects across the healthcare supply chain. Companies heavily reliant on diagnostic referrals, such as instrument maker Thermo Fisher Scientific, may face downward pressure on revenue guidance for their clinical diagnostics divisions. Conversely, outpatient surgery center operators like HCA Healthcare and UnitedHealth Group's Optum unit could benefit as care shifts away from centralized labs to integrated delivery networks, potentially capturing more revenue within their own ecosystems.
A key limitation to a purely bearish outlook is Quest Diagnostics' strong cash flow generation. The company maintains a dividend yield of 2.3%, supported by a payout ratio below 40% of earnings. This provides a floor for income-focused investors, even if growth remains muted. The counter-argument is that sustained pricing pressure could erode cash flow margins over the medium term.
Positioning data from recent CFTC reports and ETF flows shows institutional investors have been net sellers of healthcare services stocks. Flow has rotated into pharmaceutical giants with stronger pricing power and medical technology firms with innovative product cycles. Short interest in DGH has crept up to 3.5% of float, a multi-month high, indicating a growth of skeptical bets against a near-term recovery.
Two immediate catalysts will provide the next signal for the stock's direction. The company's second-quarter 2026 earnings report, scheduled for 24 July, will be scrutinized for any stabilization in revenue per requisition. The annual J.P. Morgan Healthcare Conference in January 2027 will serve as a platform for management to outline long-term strategy adjustments in response to industry shifts.
Key technical levels to monitor include the $120 support level, which represents the stock's 2024 low. A sustained break below this level could trigger further selling. On the upside, the 50-day moving average near $132 acts as initial resistance. Investors should watch the relative strength index; a reading persistently below 30 would indicate an oversold condition that may precede a technical rebound.
Future performance will be conditional on the outcome of ongoing payer contract renewals. Should Quest secure contracts with minimal price concessions, sentiment could improve. If renewed contracts come with significant rate reductions, the current underperformance trend is likely to extend.
For income-focused investors, the underperformance has increased the stock's dividend yield to 2.3%, above its five-year average. The dividend appears secure, with a conservative payout ratio and strong free cash flow coverage. However, dividend growth may stall if earnings continue to contract, making the stock a yield play rather than a growth-and-income investment in the near term.
The current underperformance during a bull market is unusual. Historically, Quest shares lagged during strong bull runs in 2017-2019 but still posted positive absolute returns. The concurrent negative absolute return and significant market lag in 2026 is more severe, reminiscent of sector-specific recessions driven by regulatory changes, such as the 2018 implementation of the Protecting Access to Medicare Act price cuts.
Over the past decade, Quest Diagnostics has traded at an average forward price-to-earnings ratio of 15.8x. The current multiple of 13.2x represents a discount of roughly 16% to its historical average. This discount reflects the market's expectation of lower future earnings growth compared to the pre-2020 period, when volume growth was more strong and pricing environment more stable.
Quest Diagnostics' significant underperformance reflects a structural challenge to its core lab business model, not just a temporary cyclical downturn.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.